Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Last Updated   May 14, 2025

Want to learn how to participate in this trial?

PLATFORMPACAN1001

OVERVIEW

  • Sexes Eligible for Study
    all
  • Age
    18+ years
  • Phase
    phase 1
  • Sites
    17 Sites
  • Status
    Enrolling by invitation

SUMMARY

The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the blood and bone marrow in which the bone marrow makes a large number of abnormal blood cells) and advanced solid tumors and metastatic castration-resistant prostate cancer (mCRPC).

CONDITIONS

  • Leukemia, Myeloid, Acute
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Non-Hodgkin
  • Myelodysplastic Syndromes
  • Cancer
  • Solid Tumor, Adult
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

ELIGIBILITY


Inclusion Criteria:

* Have participated in a parent study, with a linked intervention specific appendix (ISA) within this platform study, in which they initially received study treatment(s) prior to rolling over to this platform study
* Satisfy all ISA specific inclusion criteria
* Sign an informed consent form (ICF) (or their legally acceptable representative must sign) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the platform study with details per the relevant ISA
* Be willing and able to adhere to the lifestyle restrictions specified in the relevant ISA


Exclusion Criteria:

* Have any condition or situation which, in the opinion of the investigator, may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study
* Have unacceptable toxicities or overt disease progression observed at time of rollover to the respective ISA
* Meets any exclusion criteria within the pertinent ISA


Inclusion Criteria:

* Have participated in a parent study, with a linked intervention specific appendix (ISA) within this platform study, in which they initially received study treatment(s) prior to rolling over to this platform study
* Satisfy all ISA specific inclusion criteria

More...

DETAILS

LOCATIONS

Locations in:
Belgium, France, Japan, Moldova, Poland, Ukraine, Georgia, Greece, Taiwan, United Kingdom
Country (10) City or Province (17) Status
Belgium Gent Ghent University Hospital
France Lille Hopital Claude Huriez
France Villejuif Institut Gustave Roussy
Japan Nagoya-shi National Hospital Organization Nagoya Medical Center
Moldova Chisinau Arensia Exploratory Medicine
Poland Gdansk Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
Poland Krakow Pratia MCM Krakow
Poland Skorzewo Aidport Sp z o o
Ukraine Kyiv Medical Center of Limited Liability Company Arensia Exploratory Medicine
Georgia Tbilisi Arensia Exploratory Medicine
Japan Tokyo The Cancer Institute Hospital of JFCR
Greece Athens Alexandra Hospital
Taiwan Kaohsiung City Chang Kung Memorial Hospital
Taiwan Taichung China Medical University Hospital
Taiwan Tainan National Cheng Kung University Hospital
Taiwan Taipei City National Taiwan University Hospital
United Kingdom Plymouth University Hospitals Plymouth NHS Trust
Show More
Geo Locations

51.05, 3.71667

50.63297, 3.05858

48.7939, 2.35992

35.18147, 136.90641

47.00556, 28.8575

54.35205, 18.64637

50.06143, 19.93658

52.3906266, 16.7919124

50.45466, 30.5238

41.69411, 44.83368

35.6895, 139.69171

37.97945, 23.71622

22.61626, 120.31333

24.1469, 120.6839

22.99083, 120.21333

25.04776, 121.53185

50.37153, -4.14305

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.